Abarca, LucyRx combine to serve 9M prescription users

▤ Summary

Abarca Health and LucyRx plan to combine under a new parent company, Healthcare Revolution Partners. The merged organization will serve more than 9 million prescription-drug members and target commercial and government clients across the United States. Abarca expects its Darwin Healthcare Intelligence platform to play a central role in the combined business. The companies say the transaction will expand their clinical capabilities, strengthen their technology stack, and improve prescription care while lowering costs. They expect the deal to close in the third quarter of 2026, pending regulatory approval.

▦ Linked Companies

Abarca Health

$100M to $250M